SRR661818
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.358
- PANCREAS_BETA_CELLS+0.287
- MYOGENESIS+0.265
- SPERMATOGENESIS+0.258
- KRAS_SIGNALING_UP+0.245
- UV_RESPONSE_DN+0.209
- ANGIOGENESIS+0.181
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.180
- COAGULATION+0.144
- ESTROGEN_RESPONSE_LATE+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.528
- DNA_REPAIR-0.426
- NOTCH_SIGNALING-0.402
- WNT_BETA_CATENIN_SIGNALING-0.396
- INTERFERON_ALPHA_RESPONSE-0.391
- UNFOLDED_PROTEIN_RESPONSE-0.390
- OXIDATIVE_PHOSPHORYLATION-0.345
- MYC_TARGETS_V1-0.318
- INTERFERON_GAMMA_RESPONSE-0.302
- TGF_BETA_SIGNALING-0.301
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR656552 | GTEX | — | 0.914 |
| 2 | SRR660945 | GTEX | — | 0.877 |
| 3 | BS_NFRXNAFE | ganglioneuroblastoma | — | 0.870 |
| 4 | SRR12202469 | — | — | 0.853 |
| 5 | MNG1123 | — | — | 0.851 |
| 6 | BS_0X9EGHY2 | low-grade glioma | — | 0.850 |
| 7 | SRR613474 | GTEX | — | 0.849 |
| 8 | BS_QF5VVZX5 | Ganglioglioma | — | 0.848 |
| 9 | SRR1408113 | GTEX | — | 0.847 |
| 10 | MNG1143 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.358 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.287 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.265 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.258 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.245 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.209 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.181 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.144 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.117 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| COMPLEMENT | 0.102 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.098 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.085 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.072 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.039 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.019 | Remibrutinib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |